Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Rates were validated against existing data (ESM Methodsvalidation of transition probabilities and model structure
Glucagon-like peptide-1 (GLP-1), as one of the important targets for the treatment of type 2 diabetes mellitus (T2DM), has obvious therapeutic effect, short half-life and easy to be cleared
At 2.4 mg, the target dose for phase 3 trials, the benefit-to-risk ratio appeared optimal
Omada earned $260 million in revenue in 2025, 53% more than the year before above top-end preliminary results the company announced at the J.P
US$ 27.60
US$ 25.44
US$ 27.54
US$ 21.57
US$ 28.92
US$ 29.46
US$ 29.20
